

EGFRVIII
Catalog # PVGS1841**Specification**

EGFRVIII - Product Information

Primary Accession

[NP_001333870.1](#)**Species**

Human

Sequence

Leu25-Ser378

Purity> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC**Endotoxin Level**

Less than 1EU per µg by the LAL method.

Biological Activity

Immobilized EGFRVIII, His&Avi, Human (Cat.No.: Z03940) at 1 µg/ml (100 µl/Well) on the plate can bind Anti-EGFRVIII Antibody, hFc Tag.

Expression System

HEK293

Theoretical Molecular Weight

41.6 kDa

Formulation**Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).****Reconstitution**It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 µg/ml.**Storage & Stability**

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

EGFRVIII - Additional Information**Target Background**

Epidermal growth factor receptor (EGFR) is a transmembrane protein. It can be activated by epidermal growth factor or transforming growth factor alpha (TGF-α). EGFR plays an important role in cell survival, proliferation and angiogenesis. EGFR is highly expressed in a variety of solid tumours. It is a common target for cancer therapy.

EGFRVIII - Protein Information

EGFRVIII - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

EGFRVIII - Images